Exploring Sirtuins: New Frontiers in Managing Heart Failure with Preserved Ejection Fraction

被引：1

作者：

Lu, Ying ^{[1
]}

Li, Yongnan ^{[2
]}

Xie, Yixin ^{[1
]}

Bu, Jiale ^{[1
]}

Yuan, Ruowen ^{[1
]}

Zhang, Xiaowei ^{[1
]}

机构：

[1] Lanzhou Univ, Hosp 2, Dept Cardiol, Lanzhou 730031, Peoples R China

[2] Lanzhou Univ, Hosp 2, Dept Cardiac Surg, Lanzhou 730031, Peoples R China

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2024年 / 25卷 / 14期

基金：

中国国家自然科学基金;

关键词：

SIRTs; heart failure; heart failure with preserved ejection fraction; left ventricular diastolic dysfunction; development; treatment; DIASTOLIC FUNCTION; CARDIAC FIBROSIS; SIRT1; ACTIVATOR; SEX-DIFFERENCES; MOUSE MODEL; GENDER; PROTECTS; SRT2104; HYPERTROPHY; RESISTANCE;

D O I：

10.3390/ijms25147740

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

With increasing research, the sirtuin (SIRT) protein family has become increasingly understood. Studies have demonstrated that SIRTs can aid in metabolism and affect various physiological processes, such as atherosclerosis, heart failure (HF), hypertension, type 2 diabetes, and other related disorders. Although the pathogenesis of HF with preserved ejection fraction (HFpEF) has not yet been clarified, SIRTs have a role in its development. Therefore, SIRTs may offer a fresh approach to the diagnosis, treatment, and prevention of HFpEF as a novel therapeutic intervention target.

引用

页数：22

共 50 条

[31] Heart Failure with Preserved Ejection Fraction
Mitchell, Michelle
CURRENT EMERGENCY AND HOSPITAL MEDICINE REPORTS, 2019, 7 (04) : 184 - 188
[32] Heart Failure With Preserved Ejection Fraction
Goldsmith, Steven R.
Simegn, Mengistu
JACC-HEART FAILURE, 2019, 7 (07) : 632 - 632
[33] Heart Failure With Preserved Ejection Fraction
Rogers, Felix J.
Gundala, Teja
Ramos, Jahir E.
Serajian, Asif
JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2015, 115 (07): : 432 - 442
[34] Heart failure with preserved ejection fraction
Marzia Rigolli
Gillian A Whalley
Journal of Geriatric Cardiology, 2013, (04) : 369 - 376
[35] Exploring circulating nitric oxide in heart failure and preserved ejection fraction
Lejeune, Sibille
Lobysheva, Irina
Menghoum, Nassiba
Gruson, Damien
Horman, Sandrine
Beauloye, Christophe
Balligand, Jean-Luc
Pouleur, Anne-Catherine
ACTA CARDIOLOGICA, 2023, 78 : 13 - 14
[36] New therapy concepts for heart failure with preserved ejection fraction
Tschoepe, C.
Pieske, B.
HERZ, 2015, 40 (02) : 194 - +
[37] Toward a New SUMMIT in Heart Failure with Preserved Ejection Fraction
Felker, G. Michael
NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (05):
[38] New Drugs and Devices in the Pipeline for Heart Failure with Reduced Ejection Fraction Versus Heart Failure with Preserved Ejection Fraction
Raina A.
Kanwar M.
Current Heart Failure Reports, 2014, 11 (4) : 374 - 381
[39] The Critical Role of Comorbidities in Managing Heart Failure with Preserved Ejection Fraction (HFpEF)
Gajewski, Piotr
Zymlinski, Robert
Biegus, Jan
ESC HEART FAILURE, 2024,
[40] Diagnosing and managing patients with heart failure with preserved ejection fraction: a consensus survey
Austin, Rosalynn
Khair, Eva
Blakeman, Thomas
Hossain, Muhammad Zakir
Sowden, Emma
Chew-Graham, Carolyn
Forsyth, Faye
Deaton, Christi
Optimise HFpEF Investigators
BMJ OPEN, 2024, 14 (12):

← 1 2 3 4 5 →